Skip to main
KNSA

KNSA Stock Forecast & Price Target

KNSA Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kiniksa Pharmaceuticals is a strong investment opportunity, with its established and growing revenue stream from its key product Arcalyst and promising pipeline candidates, indicating potential for continued growth. Additional growth initiatives and strong commercial momentum also support the company's long-term outlook. However, there are risks to consider, such as potential competition and challenges in commanding premium pricing for rare disease treatments. Overall, with a strong management team and a solid financial position, the company is well-positioned for success in the biopharmaceutical market.

Bears say

Kiniksa Pharmaceuticals is currently focused on phase 2 dose-finding data expected in the second half of 2026 and plans to initiate a pivotal phase 3 study by the end of 2026 for KPL-387, a once-monthly treatment for recurrent pericarditis. Additionally, the delay in competition from LLY widens KNSA's competitive runway for their drug candidates. The company's current stock price of $59 is derived from a sum-of-parts valuation for their clinical programs, including an 8x multiple to their share of estimated US sales for Arcalyst in RP and CAPS in 2028, and an 8x multiple to estimated sales for KPL-387 in RP in 2032. While Arcalyst is currently profitable, the potential success of their next-generation RP assets could lead to further profitability and upside for the company's stock.

KNSA has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kiniksa Pharmaceuticals Ltd (KNSA) Forecast

Analysts have given KNSA a Strong Buy based on their latest research and market trends.

According to 7 analysts, KNSA has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kiniksa Pharmaceuticals Ltd (KNSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.